Kala pharmaceuticals, inc. (KALA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-21,955

-21,958

-23,176

-23,825

-25,388

-25,219

-15,603

-14,619

-11,297

-11,290

-10,176

-10,986

-9,759

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

230

229

226

218

170

109

70

92

81

74

73

71

69

Non-cash operating lease cost

473

466

467

403

437

-

-

-

-

-

-

-

-

Amortization of right-of-use assets

-

-

-

-

-

-

-

-

93

91

90

88

87

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

0

623

1,185

36

Amortization of debt discount and other non-cash interest

253

249

243

235

231

-

-

-

-

-

-

-

-

Amortization of debt discount and other non-cash interest

-

-

-

-

-

-

-

-

31

-

30

28

28

Stock-based compensation

2,497

2,325

2,572

2,621

2,473

2,198

2,265

2,291

1,861

1,501

981

567

522

Change in operating assets and liabilities:
Accounts receivable

-6,769

4,392

1,523

974

4,674

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-99

1,622

1,273

-487

-619

-1,963

3,362

-253

241

-238

584

56

92

Inventory

579

-108

424

2,899

1,056

-

-

-

-

-

-

-

-

Accounts payable

-1,332

514

-1,035

957

-3,206

4,308

-1,305

1,314

-229

131

-118

-999

1,191

Accrued expenses and other current liabilities

-6,023

6,176

1,678

2,542

-766

2,825

2,603

1,456

-2,916

2,764

-150

1,357

-1,370

Lease liabilities and other long-term liabilities

-312

-307

-667

-191

-10

-

-

-

-

-

-

-

-

Lease liabilities and other long-term liabilities

-

-

-

-

-

-

-

-

-97

-93

-93

-88

-87

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-6

-14

18

Net cash used in operating activities

-19,880

-18,212

-22,912

-20,426

-31,170

-15,989

-16,213

-9,205

-12,714

-6,564

-9,330

-8,847

-9,357

Cash flows from investing activities:
Purchases of property and equipment

292

188

204

499

444

910

127

168

373

282

89

37

72

Net cash used in investing activities

-292

-188

-204

-499

-444

-910

-127

-168

-373

-282

-89

-37

-72

Cash flows from financing activities:
Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

765

19

Proceeds from common stock offerings, net of underwriters' discounts and offering cost

130,754

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from venture debt, net of debt issuance costs of $50

-

-

-

-

-

-

0

0

2,728

-

-

-

-

Payment of principal and prepayment penalty on venture debt

-

-

-

-

-

20,180

0

0

1,667

-

-

-

-

Payment of principal on finance lease

8

0

10

10

10

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan

435

-

-

-

39

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan

-

-

-

-

-

-

-

55

28

-

-

-

-

Net cash provided by financing activities

131,181

6,295

2,668

-10

29

122,915

45

55

1,089

-637

105,117

-765

-19

Net increase/(decrease) in cash and restricted cash:

111,009

-12,105

-20,448

-20,935

-31,585

106,016

-16,295

-9,318

-11,998

-7,483

95,698

-9,649

-9,448

Reconciliation of cash and restricted cash:
Less restricted cash

-

-

-

-

-

-

-

-

-

1

-1

25

109

Non-cash investing and financing activities:
Right-of-use asset obtained in exchange for finance lease obligation

-

0

0

0

136

-

-

-

-

-

-

-

-

Purchases of property and equipment in accounts payable

-

-

-

-

409

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accruals

-

-

-

-

-

-

-

-

-

-

-

-155

613

Supplemental disclosure:
Cash paid for interest

1,875

1,896

1,943

1,821

1,862

1,903

338

394

406

331

184

178

170

Right-of-use assets obtained in exchange of operating lease obligations

-

0

0

-26

1,878

-

-

-

-

-

-

-

-